📊 BOLT Key Takeaways
Investment Thesis
Bolt Biotherapeutics is a pre-revenue stage biopharmaceutical company burning significant cash with minimal revenue generation and no clear path to profitability in the near term. The company is consuming cash at an unsustainable rate with only 11.7M in cash against 39.9M annual operating cash burn, providing approximately 3-4 quarters of runway at current burn rates. Absent major clinical trial successes or financing, the company faces severe liquidity constraints that threaten its continued operations.
BOLT Strengths
- Strong liquidity position with 3.59x current ratio and quick ratio, indicating ability to meet short-term obligations
- Minimal leverage with 0.00x debt-to-equity ratio, preserving financial flexibility for future financing
- Reduced operating losses year-over-year with diluted EPS improving 46% (though still deeply negative at -17.85)
BOLT Risks
- Severe cash burn of 39.9M annually against only 11.7M cash reserves, providing critical runway of less than 4 quarters
- Astronomical negative margins with -469.3% operating margin and -433.7% net margin indicating fundamental business model challenges
- Revenue of only 7.7M is inadequate to support R&D-heavy biopharmaceutical operations, with no gross margin visibility suggesting revenue may be contract or milestone-based rather than product sales
- Negative free cash flow of -39.9M and total losses exceeding 33M annually demonstrate unsustainable burn rate
- No long-term debt data available and minimal insider activity (3 Form 4 filings in 90 days) may indicate limited confidence from insiders
Key Metrics to Watch
- Operating cash burn rate and cash runway until liquidity crisis
- Clinical trial progress and FDA milestone achievements that could unlock revenue or financing
- Quarterly revenue trends and whether any pipeline programs are generating meaningful revenue
- Capital raise announcements or debt restructuring given critical runway constraints
BOLT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.59x current ratio provides a solid financial cushion.
BOLT Profitability Ratios
BOLT vs Healthcare Sector
How Bolt Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BOLT Balance Sheet & Liquidity
BOLT 5-Year Financial Trend
5-Year Trend Summary: Bolt Biotherapeutics, Inc.'s revenue has grown significantly by 511% over the 5-year period, indicating strong business expansion. The most recent EPS of $-33.06 indicates the company is currently unprofitable.
BOLT Growth Metrics (YoY)
BOLT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$7.1M | $-3.72 |
| Q2 2025 | $1.3M | -$8.6M | $-4.46 |
| Q1 2025 | $1.2M | -$10.8M | $-0.28 |
| Q3 2024 | $1.1M | -$15.2M | $-0.40 |
| Q2 2024 | $1.3M | -$18.1M | $-0.48 |
| Q1 2024 | $1.8M | -$10.8M | $-0.28 |
| Q3 2023 | $2.1M | -$16.3M | $-0.43 |
| Q2 2023 | $1.4M | -$18.1M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BOLT Capital Allocation
BOLT SEC Filings
Access official SEC EDGAR filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLT
What is the AI rating for BOLT?
Bolt Biotherapeutics, Inc. (BOLT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLT's key strengths?
Strong liquidity position with 3.59x current ratio and quick ratio, indicating ability to meet short-term obligations. Minimal leverage with 0.00x debt-to-equity ratio, preserving financial flexibility for future financing.
What are the risks of investing in BOLT?
Severe cash burn of 39.9M annually against only 11.7M cash reserves, providing critical runway of less than 4 quarters. Astronomical negative margins with -469.3% operating margin and -433.7% net margin indicating fundamental business model challenges.
What is BOLT's revenue and growth?
Bolt Biotherapeutics, Inc. reported revenue of $7.7M.
Does BOLT pay dividends?
Bolt Biotherapeutics, Inc. does not currently pay dividends.
Where can I find BOLT SEC filings?
Official SEC filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLT's EPS?
Bolt Biotherapeutics, Inc. has a diluted EPS of $-17.85.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.